Skip to main content

Table 1 Patient Characteristics of the Total Rectal Cancer Cohort and stratified for HLA class I, HLA-G and Foxp3+ expression

From: Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study

  Total population n = 495 HLA Class I Loss n = 70 (15%) HLA Class I Downregulationn = 105 (22%) HLA Class I Expression n = 293 (63%) HLA-G Weak n = 350 (72%) HLA-G Strong n = 134 (28%) Foxp3+ Below median n = 240 (50%) Foxp3+ Above median n = 238 (50%)
Gender (%)         
Male 316 (63.8%) 49 (70.0%) 63 (60.0%) 186 (63.5%) 227 (64.9%) 83 (61.9%) 162 (67.5%) 142 (59.7%)
Female 179 (36.2%) 21 (30%) 42 (40.0%) 107 (36.5%) 123 (35.1%) 51 (38.1%) 78 (32.5%) 96 (40.3%)
Age in years (mean SD) 64.5 (11.3) 64.8 (12.2) 65.5 (11.0) 64.0 (11.0) 64.7 (11.1) 63.9 (11.7) 64.7 (11.9) (64.2 (10.5)
TNM stage (%)         
I 134 (27.1%) 9 (12.9%) 27 (25.7%) 89 (30.4%) 80 (22.9%) 50 (37.3%) 43 (17.9%) 85 (35.7%)
II 136 (27.5%) 19 (27.1%) 25 (23.8%) 90 (30.7%) 98 (28.0%) 37 (27.6%) 65 (27.1%) 71 (29.8%)
III 193 (39.0%) 33 (47.1%) 51 (48.6%) 96 (32.8%) 146 (41.7%) 41 (30.6%) 112 (46.7%) 72 (30.3%)
IV 32 (6.5%) 9 (12.9%) 2 (1.9%) 18 (6.1%) 26 (7.4%) 6 (4.5%) 20 (8.3%) 10 (4.2%)
Tumor grade (%)         
Moderate 358 (72.3%) 41 (58.6%) 72 (68.9%) 228 (77.8%) 248 (70.9%) 102(76.1%) 160 (66.7%) 185 (77.7%)
Poor 110 (22.2%) 23 (32.9%) 25 (23.8%) 54 (18.4%) 83 (23.7%) 25 (18.7%) 67 (27.9%) 40 (16.8%)
Well 25 (5.1%) 5 (7.1%) 8 (7.6%) 10 (3.4%) 17 (4.9%) 7 (5.2%) 12 (5.0%) 12 (5.0%)
Missing 2 (0.4%) 1 (1.4%)   1 (0.3%) 2 (0.6%)   1 (0.4%) 1 (0.4%)
Adjuvant therapy         
No 402 (81.2%) 46 (65.7%) 84 (80%) 253 (86.3%) 278 (79.4%) 116 (86.6%) 185 (77.1%) 205 (86.1%)
Yes 75 (15.2%) 19 (27.1%) 19 (18.1%) 31 (10.6%) 58 (16.6%) 14 (10.4%) 44 (18.3%) 28 (11.8%)
Missing 18 (3.6%) 5 (7.1%) 2 (1.9%) 9 (3.1%) 14 (4.0%) 4 (3.0%) 11 (4.6%) 5 (2.1%)
Circumferential margin         
Negative 397 (80.2%) 49 (70.0%) 83 (79.0%) 242 (82.6%) 279 (79.7%) 110 (82.1%) 188 (78.3%) 196 (82.4%)
Positive 98 (19.8%) 21 (30.0%) 22 (21.0%) 51 (17.4%) 71 (20.3%) 24 (17.9%) 52 (21.7%) 42 (17.6%)
  1. This table shows the patient characteristics of the entire rectal cancer cohort (n = 495) and stratified for HLA class I, HLA-G and Foxp3+ staining.